Genmab — Oktober 2023
-
Det med bud, er jo noget, de fleste drømmer om. Men samtidigt de færreste, der oplever
-
Jep
-
Den var så til @gdn55
-
Det er rent gætteværk p.t., om vi skal den ene eller anden vej. Det er samarbejdet, der er helt afgørende i.m.h.
-
Og, @Riis7. Det er jo ikke nyt
-
I princippet har 'dommeren' allerede underkendt den tidligere afgørelse. Hvis den stod ved magt, skulle anken have været afvist med det samme ( i henhold til reglerne).YHvis 'dommerne' dengang havde haft et solidt og entydigt juridisk argument, så havde de vel brugt det i stedet for en uforståelig ikke-afgørelse. Så uden at være decideret optimist, ser jeg jeg sagen som ret åben.
-
Expansion Trial of Epcoritamab Shows Promising Antitumor Activity in Patients With High-Risk Relapsed/Refractory CLL https://www.targetedonc.com/view/expansion-trial-of-epcoritamab-shows-promising-antitumor-activity-in-patients-with-high-risk-relapsed-refractory-cll
-
Jeg kunne sbsolut hår, at du har ret @gentogen.
-
absolut håbe…
-
Natten mellem fredag og lørdag - en gang ude i fremtiden. Tættere på, kommer jeg ikke
-
"Responses were seen early, frequently, and appeared durable, with about 83% of responders remaining in response at 9 months. “The objective response rate (ORR) was 82% with a complete response (CR) rate of 33%, which I thought was quite encouraging, especially in difficult-to-treat, high-risk patients with [R/R CLL]” Kater said.
-
Fokuspunkterne i de største danske 3. kvartalsregnskaber https://www.proinvestor.com/boards/116053
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind